ENGLEWOOD, Colo. , June 25, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has been awarded UK patent 2617515 for a multiparameter, noninvasive sepsis monitor.

Sepsis is a life-threatening condition characterized by systemic inflammation and organ dysfunction caused by an infection. Over half of sepsis cases are contracted in hospitals and have a high mortality rate due to the difficulty of early detection and diagnosis¹. According to the Centers for Disease Control (CDC), at least 1.7 million people have sepsis each year in the United States alone, and in hospitals, 1 in 3 deaths is related to sepsis². On a global scale, sepsis kills 11 million people annually, accounting for roughly 20% of global deaths, and roughly half of sepsis cases are children under 5 years of age³.

"Sepsis is a global health crisis with a mortality rate among the highest of any medical issue," said Thomas Sandgaard, Founder and CEO of Zynex. "We have an opportunity to develop a noninvasive, highly accurate monitor that can provide real time information to clinicians that could help to drastically reduce this. We will develop this technology by leveraging our competencies of cardiac monitoring technologies."

This device is envisioned to continuously monitor multiple physiological signals to provide early alerts to clinicians about a patient's trends and sepsis status. The Surviving Sepsis Campaign, which is led by critical care physicians, has highlighted for decades that early detection and treatment is vital in ensuring a patient's recovery from sepsis⁴. Late diagnosis delays treatment, leading to a higher economic burden and increased mortality rates.

Donald Gregg, President of Zynex Monitoring Solutions, commented, "We believe that we can significantly contribute to the earlier detection of sepsis leading to a reduction in mortality from this deadly condition. This product would be derived from our growing portfolio of noninvasive monitoring technologies."

[1] Markwart R et al., Epidemiology and burden of sepsis acquired in hospitals and intensive care units: a systematic review and meta-analysis. Intensive Care Med. 2020. 46(8):1536-1551.
[2] About Sepsis. 2024. CDC: Sepsis. March 8, 2024. https://www.cdc.gov/sepsis/about/index.html.
[3] Sepsis. 2024. World Health Organization (WHO).May 3, 2024. https://www.who.int/news-room/fact-sheets/detail/sepsis
[4] Dellinger RP, et al., Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004. 32(3):858-73.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. our results of operations and the plans, strategies and objectives for future operations; the timing and scope of any potential stock repurchase; and other similar statements.

Words such as "anticipate," "believe," "continue," "could," "designed," "endeavor," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," "target," "preliminary," "will," "would" and similar expressions are intended to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward-looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products; the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources; the need to keep pace with technological changes; our dependence on the reimbursement for our products from health insurance companies; our dependence on first party manufacturers to produce our products on time and to our specifications' implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy; market conditions; the timing, scope and possibility that the repurchase program may be suspended or discontinued; economic factors, such as interest rate fluctuations; and other risks described in our filings with the Securities and Exchange Commission.

These and other risks are described in our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2024, as well as our quarterly reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statements contained in this press release represent Zynex's views only as of today and should not be relied upon as representing its views as of any subsequent date. Zynex explicitly disclaims any obligation to update any forward-looking statements, except to the extent required by law.

About Zynex, Inc.

Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.

Investor Relations Contact:
Dan Moorhead, CFO
ir@zynex.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/zynex-announces-award-of-uk-patent-for-non-invasive-detection-of-sepsis-302490592.html

SOURCE Zynex, Inc.